

**Table 2b. Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2011–2016 and cumulative—United States and 6 dependent areas**

	2011		2012		2013		2014		2015		2016		Cumulative <sup>a</sup>
	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.	Rate <sup>b</sup>	No.
<b>Age at diagnosis (yr)</b>													
<13 <sup>c</sup>	19	0.0	11	0.0	9	0.0	71	0.1	40	0.1	39	0.1	10,000
13–14	43	0.5	29	0.3	29	0.3	15	0.2	9	0.1	12	0.1	1,538
15–19	442	2.0	357	1.6	406	1.9	193	0.9	191	0.9	212	1.0	9,542
20–24	2,002	8.9	1,933	8.4	2,031	8.8	1,371	5.9	1,307	5.7	1,266	5.6	55,326
25–29	2,833	13.1	2,809	13.0	2,816	12.9	2,360	10.6	2,392	10.6	2,438	10.5	149,471
30–34	3,210	15.4	3,299	15.6	2,973	13.8	2,446	11.2	2,437	11.2	2,405	10.9	235,471
35–39	3,298	16.6	3,017	15.3	2,878	14.5	2,453	12.2	2,273	11.1	2,347	11.2	254,080
40–44	3,881	18.2	3,551	16.7	3,144	14.9	2,538	12.2	2,243	11.0	2,077	10.4	213,477
45–49	4,081	18.2	3,767	17.1	3,395	15.8	2,730	12.9	2,450	11.6	2,194	10.4	147,932
50–54	2,985	13.1	2,965	13.0	2,846	12.5	2,347	10.3	2,308	10.2	2,197	9.9	90,220
55–59	1,846	9.0	1,825	8.7	1,834	8.6	1,623	7.5	1,503	6.8	1,529	6.9	50,882
60–64	932	5.2	1,032	5.7	1,057	5.8	872	4.6	845	4.4	926	4.7	27,308
≥65	761	1.8	760	1.7	785	1.7	754	1.6	740	1.5	767	1.5	23,348
<b>Race/ethnicity</b>													
American Indian/Alaska Native	99	—	91	—	85	—	86	—	93	—	102	—	3,581
Asian <sup>d</sup>	350	—	355	—	345	—	323	—	321	—	336	—	10,124
Black/African American	12,275	—	11,975	—	11,219	—	9,079	—	8,632	—	8,504	—	509,200
Hispanic/Latino <sup>e</sup>	5,976	—	5,689	—	5,541	—	4,581	—	4,305	—	4,350	—	267,013
Native Hawaiian/ Other Pacific Islander	31	—	25	—	22	—	17	—	26	—	20	—	864
White	6,379	—	6,094	—	5,859	—	4,828	—	4,631	—	4,443	—	440,117
Multiple races	1,223	—	1,126	—	1,132	—	859	—	730	—	654	—	37,604
<b>Transmission category<sup>f</sup></b>													
<b>Male adult or adolescent</b>													
Male-to-male sexual contact	13,612	—	13,332	—	13,134	—	10,513	—	10,155	—	10,157	—	605,555
Injection drug use	1,759	—	1,652	—	1,424	—	1,229	—	1,057	—	993	—	198,978
Male-to-male sexual contact and injection drug use	1,279	—	1,206	—	1,018	—	791	—	800	—	769	—	90,494
Heterosexual contact <sup>g</sup>	2,928	—	2,743	—	2,638	—	2,232	—	2,038	—	2,045	—	91,070
Other <sup>h</sup>	126	—	112	—	129	—	81	—	101	—	82	—	11,900
<b>Subtotal</b>	<b>19,704</b>	<b>15.4</b>	<b>19,045</b>	<b>14.8</b>	<b>18,344</b>	<b>14.1</b>	<b>14,845</b>	<b>11.3</b>	<b>14,150</b>	<b>10.7</b>	<b>14,047</b>	<b>10.5</b>	<b>997,997</b>
<b>Female adult or adolescent</b>													
Injection drug use	1,311	—	1,200	—	1,051	—	869	—	794	—	736	—	94,118
Heterosexual contact <sup>g</sup>	5,168	—	4,994	—	4,659	—	3,896	—	3,675	—	3,478	—	160,285
Other <sup>h</sup>	131	—	105	—	141	—	92	—	79	—	109	—	6,195
<b>Subtotal</b>	<b>6,610</b>	<b>4.9</b>	<b>6,299</b>	<b>4.7</b>	<b>5,850</b>	<b>4.3</b>	<b>4,857</b>	<b>3.5</b>	<b>4,548</b>	<b>3.3</b>	<b>4,323</b>	<b>3.1</b>	<b>260,598</b>
<b>Child (&lt;13 yrs at diagnosis)</b>													
Perinatal	15	—	9	—	8	—	61	—	31	—	32	—	9,099
Other <sup>i</sup>	4	—	2	—	1	—	10	—	9	—	7	—	901
<b>Subtotal</b>	<b>19</b>	<b>0.0</b>	<b>11</b>	<b>0.0</b>	<b>9</b>	<b>0.0</b>	<b>71</b>	<b>0.1</b>	<b>40</b>	<b>0.1</b>	<b>39</b>	<b>0.1</b>	<b>10,000</b>
<b>Region of residence<sup>j</sup></b>													
Northeast	5,106	9.2	4,744	8.5	4,329	7.7	3,508	6.3	3,303	5.9	3,088	5.5	354,229
Midwest	3,250	4.8	3,115	4.6	2,957	4.4	2,476	3.7	2,329	3.4	2,359	3.5	132,116
South	13,163	11.3	12,847	11.0	12,544	10.6	10,134	8.5	9,742	8.0	9,584	7.8	501,523
West	4,310	5.9	4,194	5.7	3,928	5.3	3,291	4.4	3,106	4.1	3,129	4.1	244,478
U.S. dependent areas	504	12.4	455	11.3	445	11.2	364	9.3	258	6.7	249	6.5	36,249
<b>Total<sup>k</sup></b>	<b>26,333</b>	<b>8.3</b>	<b>25,355</b>	<b>8.0</b>	<b>24,203</b>	<b>7.6</b>	<b>19,773</b>	<b>6.1</b>	<b>18,738</b>	<b>5.8</b>	<b>18,409</b>	<b>5.6</b>	<b>1,268,595</b>

Note. Data for the year 2016 are preliminary (subject to change) because they are based on only a 6-month reporting delay. Data for the year 2016 should not be used when assessing trends. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

<sup>a</sup> From the beginning of the epidemic through 2016.

<sup>b</sup> Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category because of the lack of denominator data.

<sup>c</sup> The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).

<sup>d</sup> Includes Asian/Pacific Islander legacy cases (see Technical Notes).

<sup>e</sup> Hispanics/Latinos can be of any race.

<sup>f</sup> Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

<sup>g</sup> Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

<sup>h</sup> Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

<sup>i</sup> Includes hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>j</sup> Data are based on residence at time of stage 3 (AIDS) classification.

<sup>k</sup> Cumulative total includes 92 persons whose race/ethnicity is unknown.